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For more than 60 years, the mood stabilizer lithium has been used alone or in combination
for the treatment of bipolar disorder, schizophrenia, depression, and other mental
illnesses. Despite this long history, the molecular mechanisms trough which lithium
regulates behavior are still poorly understood. Among several targets, lithium has been
shown to directly inhibit glycogen synthase kinase 3 alpha and beta (GSK3α and GSK3β).
However in vivo, lithium also inhibits GSK3 by regulating other mechanisms like the
formation of a signaling complex comprised of beta-arrestin 2 (βArr2) and Akt. Here, we
provide an overview of in vivo evidence supporting a role for inhibition of GSK3 in some
behavioral effects of lithium. We also explore how regulation of GSK3 by lithium within
a signaling network involving several molecular targets and cell surface receptors [e.g.,
G protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs)] may provide
cues to its relative pharmacological selectivity and its effects on disease mechanisms. A
better understanding of these intricate actions of lithium at a systems level may allow the
rational development of better mood stabilizer drugs with enhanced selectivity, efficacy,
and lesser side effects.
Keywords: lithium, glycogen synthase kinase 3, arrestin, Akt, mood stabilizer, bipolar disorder, pharmacology,
protein-protein interactions
INTRODUCTION
Lithium is an alkali metal that is used medically under the form
of a cationic salt Li+ in association with carbonate (COO−) or
citrate. Lithium salts have been used medically since the late
nineteenth century for instance as part of popular tonics such as
the “Bib-Label Lithiated Lemon-Lime Soda” better known under
the name of 7UP (Williams and Harwood, 2005). The first publi-
cation on the use of lithium to treat acute mania was published by
John Cade more than 60 years ago (Cade, 1949). However, it took
22 years for the U.S. food and Drug administration to approve
lithium for the treatment of bipolar disorder. Over time, lithium
has become a gold standard for the management of bipolar
mood disorders and cyclothymia. Each of these mental illnesses
affects 1–2% of the population and is characterized by alternating
episodes of manic and depressive symptoms (Cade, 1949; Schou
et al., 1954; Blanco et al., 2002). Lithium has been reported to
reduce suicide rates and prevent manic episodes in individuals
with bipolar disorder, major depression, or schizoaffective disor-
ders (Bowden, 2000; Cipriani et al., 2005; Muller-Oerlinghausen
et al., 2005; Tondo and Baldessarini, 2009). Lithium is also used as
part of combination therapies for augmenting the effects of other
psychoactive drugs such as antidepressants and antipsychotics
affecting monoaminergic neurotransmission (DeMontigny et al.,
1981; Valenstein et al., 2006).
Despite important clinical applications, the molecular mech-
anisms by which lithium exerts its therapeutic effects in mental
disorders are still not well understood (Phiel and Klein, 2001;
Beaulieu andCaron, 2008).Over the years, lithiumhasbeen shown
to inhibit various enzymes directly in vitro (Figure 1). These
include inositol monophosphatases (IMPAs) (Berridge et al.,
1989), bisphosphate 3′-nucleotidase (BPNT1) (Spiegelberg et al.,
2005), cyclooxygenase (COX) (Rapoport and Bosetti, 2002) and
isoforms of glycogen synthase kinase 3 (GSK3) (Klein andMelton,
1996; Stambolic et al., 1996; Phiel and Klein, 2001). Studies con-
ducted using different cellular models or organisms (e.g., Mus.
musculus, Caenorhabditis elegans or Dictyostelium discoideum)
have documented the importance of these effects of lithium on
different physiological or pathological processes including devel-
opmentandepilepsy(KleinandMelton,1996;Williamsetal., 2002;
Shaldubina et al., 2006; Cryns et al., 2007, 2008). However, the
relative involvement of these direct molecular targets of lithium in
behavioral effects that would be clinically relevant to depression
or mania has often not been demonstrated. Furthermore, it is
also unclear how the action of lithium on ubiquitously expressed
molecules that are mostly involved in the regulation of cell sig-
naling and not to specific neurotransmitter systems can explain
its relative selectivity as a therapeutic agent in psychiatry.
Here we provide an overview of several independent line
of evidence suggesting that lithium can exert “anti-manic” and
“antidepressant” like effects by affecting the activity of GSK3α
and β both as a direct inhibitor and as a modulator of cell sig-
naling pathways regulating the activity of these kinases. We also
speculate on the possible importance of such intricate regulation
mechanisms for lithium efficacy in several types of combination
therapies and for its relative clinical selectivity.
THE REGULATION OF GSK3 SIGNALING BY AKT AND CELL
SURFACE RECEPTORS
The GSK3 family of serine threonine kinases is composed of
two isoenzymes/paralogous proteins GSK3α and GSK3β, which
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FIGURE 1 | Schematic representation of different direct molecular
targets of lithium. These include inositol monophosphatases (IMPAs),
Bisphosphate 3′-nucleotidase (BPNT), cyclooxygenase (COX), beta-arrestin
2 (βArr2), and members of the glycogen synthase kinase 3 alpha and beta
(GSK3α and β). Since the mechanism by which lithium would inhibit several
of these molecules is by competing with magnesium ions (Mg2+) acting as
a co-factor we also included the possibility that other molecular targets may
be affected through such competition.
were originally identified for their role in insulin receptors
signaling (Embi et al., 1980; Parker et al., 1983; Woodgett,
1990; Cross et al., 1995). Since then, the biological roles of
these kinases have been demonstrated to be much broader,
including implications in the regulation of development, immu-
nity/inflammation, cancer, neurotransmission, and several other
biological processes (Cohen and Frame, 2001; Woodgett, 2001;
Kaidanovich-Beilin and Woodgett, 2011). GSK3 is constitutively
active in cells under resting/unstimulated conditions (Sutherland
et al., 1993; Stambolic and Woodgett, 1994) and is primarily reg-
ulated through inhibition of its activity either by phosphorylation
or the regulation of its incorporation into protein complexes. For
instance activation of phosphoinositide 3-kinase (PI3K) signal-
ing regulates GSK3 by increasing its phosphorylation on negative
regulatory serine residues (Sutherland et al., 1993; Stambolic and
Woodgett, 1994; Sutherland and Cohen, 1994; Cross et al., 1995).
In contrasts, activation of canonical Wnt signaling prevents the
action of GSK3 on βcatenin by preventing the formation of a pro-
tein complex involving adenomatous polyposis coli (APC) and
axin that targets active GSK3 to βcatenin (Behrens et al., 1998;
Kishida et al., 1998).
The activity of GSK3α/β is positively regulated by phosphory-
lation on tyrosine residues (Thy 279 for GSK3α and Thy 216 for
GSK3β) (Hughes et al., 1993; Lochhead et al., 2006) and nega-
tively regulated by serine phosphorylation (Ser 21 for GSK3α and
Ser 9 for GSK3β) that are situated in the N-terminal domains of
these kinases (Sutherland et al., 1993; Stambolic and Woodgett,
1994; Sutherland and Cohen, 1994; Cross et al., 1995). While sev-
eral serine/threonine kinases can phosphorylate these domains,
the most prevalent negative regulators of GSK3 are members of
a small family of kinases termed Akt. In mammals, this family
is composed of three isoforms (Akt1, 2, and 3) that are them-
selves regulated by PI3K signaling that leads to an activatory
phosphorylation of two residues (Alessi and Cohen, 1998). The
Thr 308 residue of Akt1 is phosphorylated by phosphatidyl-
dependant kinases, PDK1 and the Ser 473 residue is phosphory-
lated by the PDK2/rictor-mTOR, in response to PI3K signaling
(Scheid and Woodgett, 2001; Jacinto et al., 2006). Of these two
phosphorylation events, phosphorylation of Akt on Thr 308 has
been shown to be essential and sufficient for the regulation of
GSK3 by Akt (Jacinto et al., 2006). Over the years, myriads of cell
surface receptors including several G protein coupled receptors
(GPCRs) and most receptor tyrosine kinases (RTKs) have been
shown to be involved in the activation of Akt isoforms via PI3K
mediated signaling (Lemmon and Schlessinger, 2010; Liao and
Hung, 2010; Beaulieu, 2011; Swift et al., 2011).
In addition to these kinase-mediated mechanisms, phos-
phatases are also playing a role in the regulation of Akt and
GSK3 activity. For instance, the serine/threonine protein phos-
phatase 1 (PP1) is known to dephosphorylate the N-terminal
serine residues of GSK3, therefore leading to its activation (Zhang
et al., 2003). The protein phosphatase 2A (PP2A) has also been
shown to participate in the inhibition of Akt (Beaulieu et al.,
2005). Importantly, there is evidence for a regulation of Akt
activity by PP2A in response to GPCR stimulation. Activation
of the dopamine receptor 2 (D2R) has been shown to stim-
ulate the inactivation of Akt by PP2A (Beaulieu et al., 2005;
Beaulieu and Gainetdinov, 2011), therefore providing a mecha-
nism through which GPCR activation can inhibit Akt in response
to extracellular signals.
As a general mechanism, activation of GPCR leads to the acti-
vation of their cognate G proteins, which is rapidly followed by
homologous receptor desensitization. This latter process involves
the phosphorylation of the GPCR by GPCR kinases and the
recruitment of the adaptor proteins β-arrestin 1 and β-arrestin
2 (βArr2) (Lohse et al., 1990; Ferguson et al., 1996). The recruit-
ment of β-arrestins to GPCR leads to an uncoupling of the G pro-
tein and to clathrin mediated receptor internalization. However,
β-arrestins can also participate to GPCR signaling by acting as
molecular scaffolds for signaling molecules such as kinases and
phosphatases (Luttrell et al., 1999; Luttrell and Gesty-Palmer,
2010). In the specific case of D2R, activation of the receptor by
dopamine promotes the formation of a signaling complex com-
posed of Akt, βArr2, and PP2A, which favor the dephosphoryla-
tion of Akt on Thr 308 and Akt inactivation. This in turn results in
an activation of GSK3 by dopamine (Beaulieu et al., 2004, 2005).
This mechanism of D2R signaling appears to play important roles
in the regulation of locomotor behavior and sensory motor gat-
ing by dopamine (Beaulieu et al., 2004; Emamian et al., 2004).
It could also contribute to the therapeutic and/or adverse effects
of psychoactive drugs like amphetamines and antpsychotics that
act on dopamine neurotransmission (Emamian et al., 2004; Masri
et al., 2008; Beaulieu et al., 2009).
DIRECT AND INDIRECT REGULATION OF GSK3 BY LITHIUM
In 1996, two independent studies (Klein and Melton, 1996;
Stambolic et al., 1996) of the effects of lithium on cell signal-
ing and development have identified a direct effect of lithium
on the activity of GSK3 both in vitro and in cells. However, the
therapeutic relevance of this finding has been unclear mostly
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because the high Ki values of lithium for GSK3α (∼3.5mM)
and GSK3β (∼2.0mM) are superior to therapeutic lithium serum
concentrations in humans (0.5–1.2mM) (Phiel and Klein, 2001;
Gould et al., 2004; Beaulieu and Caron, 2008; Beaulieu et al.,
2008). However, these values can be affected by experimental
conditions including the availability ofMg2+ ions in the assay sys-
tem. Indeed, one hypothesis explaining the inhibition of GSK3
by lithium is that Li+ ions act as uncompetitive inhibitors for
the binding of the co-factor magnesium to GSK3 (Ryves and
Harwood, 2001). Magnesium and lithium share similar ionic
radii (0.072 and 0.076 nm, respectively) and it has been sug-
gested long ago (Birch, 1974) that this may explain several of the
biochemical effects of lithium since Mg2+ is a cofactor for multi-
ple enzymes (Figure 1). The proposed competitive mechanism of
inhibition by lithium predicts that the in vivo inhibition of GSK3
may be greater than inhibition levels observed in vitro at optimal
concentrations of magnesium ions (Ryves and Harwood, 2001).
In addition to direct inhibition, lithium can also affect both
isoforms of GSK3 indirectly by activating Akt (Figure 2). This
results in an increased phosphorylation/inactivation of these
kinases by Akt in cultured neurons (Chalecka-Franaszek and
Chuang, 1999). A similar activation of Akt by lithium has also
been found in the striatum, frontal cortex, and hippocampus of
rodents following either acute or chronic treatment with lithium
under conditions resulting in lithium brain concentrations that
FIGURE 2 | Schematic representation of signaling pathways regulating
the activity of brain GSK3 and its regulation by lithium. Activation of
different cell surface receptors activates Phosphatidylinositol 3-kinases
(PI3K) that in turn phosphorylates Phosphatidylinositol 4,5-bisphosphate
(PIP2) into Phosphatidylinositol (3,4,5)-triphosphate (PIP3). Availability of
PIP3 causes the co-recruitment of the 3-phosphoinositide dependent
protein kinase-1 (PDK1) and Akt to the cell membrane and the activation of
Akt by PDK1. Phosphorylation of N-terminal serine residues of glycogen
synthase kinase 3 (GSK3) isoforms by activated Akt results in GSK3
inactivation. Conversely, activation of the D2 dopamine receptor (D2R) and
potentially of other G protein coupled receptors (GPCR) triggers the
formation of a signaling complex composed of Akt, beta-arrestin 2 (βArr2),
and protein phosphatase 2A (PP2A) that results in an inactivation of Akt and
concomitant relived GSK3 inhibition. Lithium can affect the equilibrium of
this signaling network by inhibiting GSK3 directly and by disrupting the
assembly of the Akt;βArr2;PP2A signaling complex. In addition, activated
GSK3 would contribute to its own regulation by Akt by stabilizing the
formation of this same protein complex.
are compatible with therapeutic serum concentrations in humans
(De Sarno et al., 2002; Beaulieu et al., 2004).
The activation of Akt by lithium is explained in part by an
effect of lithium on the regulation of Akt by βArr2 and the
D2R. Co-immunoprecipitation studies conducted both in vitro
and in vivo, have shown that the Akt:βArr2:PP2A signaling com-
plex can be dissociated in response to therapeutically relevant
lithium concentrations, thus providing a mechanism for the acti-
vation of Akt by lithium (Beaulieu et al., 2008). In support to
this, both chronic and acute lithium treatment failed to activate
Akt and increase GSK3 phosphorylation in mice lacking βArr2, in
which the Akt:βArr2:PP2A signaling complex cannot be formed
(Beaulieu et al., 2008). Furthermore, lithium also failed to reg-
ulate GSK3 phosphorylation in mice with reduced Akt1 activity
(Pan et al., 2011). The exact detailed mechanism through which
lithium interferes with the formation of the Akt;βArr2;PP2A
signaling complex is only partially understood. In vitro exper-
iments with recombinant purified Akt1 and βArr2 suggest that
the interactions of these two proteins and thus complex for-
mation, requires magnesium (Beaulieu et al., 2008). Therefore,
competition between lithium and magnesium could underlie
the instability of the Akt;βArr2;PP2A signaling complex in the
presence of lithium (Birch, 1974; Beaulieu et al., 2008).
The direct inhibition of GSK3 by lithium also appears to con-
tribute to the activation of Akt (Figure 2). Early experiments
conducted in cells have suggested that GSK3may promote its own
activation by preventing the activation of Akt (Zhang et al., 2003).
GSK3β has also been shown to interact with βArr2 (Beaulieu
et al., 2005). Experiments conducted using transgenic mice over-
expressing frog GSK3β in neurons, suggest the existence of a feed
forward mechanism by which GSK3 promotes its own activation
by stabilizing the Akt;βArr2;PP2A signaling complex (O’Brien
et al., 2011). According to this model, direct inhibition of GSK3
would constitute an additional mechanism that can promote the
disassembly of the Akt;βArr2;PP2A signaling complex in response
to lithium. Interestingly, such feedback effects resulting from
GSK3 inhibition may also contribute to strengthen the effects of
lithium under other conditions. For instance there is evidence
that GSK3 can regulate its own activation by phosphorylation of
the Thy 279/Thy 216 residues (Lochhead et al., 2006). In addition,
GSK3 can dampen PI3K signaling by destabilizing the insulin
receptor substrate 1 (IRS1) protein that contributes to PI3K
and Akt activation downstream of the insulin receptor (Eldar-
Finkelman and Krebs, 1997; Liberman et al., 2008; Waraich et al.,
2008). Therefore, it would be interesting to examine how such
effects of GSK3 inhibition at the level of signaling networks can
contribute to the amplification and maintenance of the effects of
lithium in different cell types or organs.
EVIDENCE FOR A ROLE OF AKT AND GSK3 SIGNALING
IN THE BEHAVIORAL EFFECTS OF LITHIUM
To our knowledge, there is no human study implicating GSK3
or any of the other potential molecular targets of lithium in its
therapeutic effects. Furthermore, research has been hindered by
a lack of a good animal model of bipolar disorder with con-
struct validity. However, behavioral tests with predictive validity
for antimanic or antidepressant drug effects have been used
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extensively. Interestingly, inhibition of GSK3 activity seems to
replicate both the “antidepressant” and “antimanic” like effects
of these drugs in rat and mice, at least in some genetic back-
grounds (Beaulieu et al., 2004, 2008; Kaidanovich-Beilin et al.,
2004; O’Brien et al., 2004; Mines et al., 2010).
While reduction of GSK3 activity does replicate several behav-
ioral effects of lithium it remains improbable that direct inhibi-
tion of GSK3 by lithium solely explains its effects on behavior.
One major reason for this is that lithium concentrations in excess
of therapeutic concentrations are often necessary to inhibit GSK3
in cell based assays (Kremer et al., 2011). Furthermore, molecules
acting upstream of GSK3 also appear to be essential for the
behavioral effects of lithium. Indeed, βArr2-KO mice, in which
lithium does not affect the phosphorylation of Akt (Thr 308) and
GSK3β (Ser 9), have been shown not to respond behaviorally to
either chronic or acute lithium treatment (Beaulieu et al., 2008).
Similarly, a recent study conducted on different strains of inbred
mice has shown that lithium fails to affect the phosphorylation
of Thr 308Akt in DBA/2J mice (Pan et al., 2011). This lack of
an effect of lithium on Akt phosphorylation was accompanied by
a lack of antimanic and antidepressant like behavioral responses
to lithium in these mice. Importantly, increased expression of
Akt1 using a herpes simplex (HSV) viral vectors in the brain
of DBA/2J mice restored lithium sensitivity (Pan et al., 2011).
Therefore, not only βArr2 but also Akt1 would be necessary for
the regulation of GSK3β Ser 9 phosphorylation and behavior
by lithium. However, the effects of lithium have not been tested
in these behavioral paradigms in mice lacking a functional Akt1
gene and it remains possible that the effects observed in DBA/2J
mice might be associated to other characteristics of this genetic
background.
The overall picture emerging from several studies of the role
of GSK3 in the effects of lithium suggests a contribution of this
kinase to at least some of its actions on behavior. However, this is
based mostly on studies conducted with rodents using tests that
were developed to predict the “antimanic” or “antidepressant”
like effects of drugs. In the absence of a better understanding of
the etiology of bipolar disorder, it may be more difficult to estab-
lish the exact contribution of GSK3 inhibition to the treatment of
this psychiatric condition. That being said, a convergence of phar-
macological and genetic evidences also supports the role of GSK3
in mood regulation as well as in the action of several drugs used
for the management of psychiatric illnesses (Beaulieu et al., 2011;
Jope, 2011). In this context, a contribution of GSK3 inhibition to
the clinical effects of lithium provides a working model that may
explain its relative clinical selectivity as well as its efficacy as an
augmentation agent for other psychoactive drugs.
CONVERGENCE OF ACTIONS, MULTIPLE HITS, AND TARGET
SELECTIVITY
The Akt1/GSK3 pathway sits at a convergence of several signal-
ing mechanisms that have been associated to mental disorders
(Figure 1). Among those, partial loss of function mutations in
the genes encoding cognate ligands for the RTKs tropomyosin-
receptor-kinaseB (TrkB) and epidermal growth factor receptor
family 4 (ErbB-4) have been associated with enhanced risk for
bipolar disorder, depression and schizophrenia (Neves-Pereira
et al., 2002; Law et al., 2007; Jaaro-Peled et al., 2009; Schmidt and
Duman, 2010). By reducing the activation of PI3K signaling, such
genetic variation should result in a reduction in the activity of Akt
and increased GSK3 activation. Similarly, genetic variation affect-
ing the well-established negative regulator of GSK3—Akt1— and
of potential negative GSK3 regulator—disrupted in schizophre-
nia 1 (Disc1)—have also been associated with bipolar disorder
and schizophrenia (Emamian et al., 2004; Chubb et al., 2008;
Kvajo et al., 2008; Mao et al., 2009). This suggests that sev-
eral genetic risk factors for mental illnesses could lead to an
increase in brain GSK3 activity. In contrast, lithium, antidepres-
sant, and several antipsychotics have been shown to increase the
inhibitory N-terminal phosphorylation of brain GSK3 in rodents
(Beaulieu et al., 2004, 2009; Emamian et al., 2004; Li et al.,
2004). Taken together, these observations suggest that inhibi-
tion of GSK3 is a plausible model for the action of lithium that
may allow to reconcile its therapeutic effects with disease eti-
ology, at least in some patient populations. Furthermore, this
model predicts that lithium and several other psychoactive drugs
may have an additive effect on GSK3 by inhibiting its activ-
ity trough different mechanisms that would complement and/or
facilitate each other. Such a “multiple hit” inhibition of GSK3
by several drugs acting through different mechanisms may be
one of the reasons underlining their mutual reinforcing effects in
the clinic.
Interestingly, lithium also appears to inhibit GSK3 in vivo
through a combination of mechanisms including its direct and
indirect inhibition following Akt activation (Figure 2). This sec-
ond type of inactivation mechanism would involve the disruption
of a protein complex that is held together by βArr2 and sta-
bilized by GSK3 (Beaulieu et al., 2008; O’Brien et al., 2011).
While the direct inhibition of GSK3 by lithium is a relatively
simple general mode of action that can affect all cells, its inhi-
bition by an Akt/βArr2 dependent mechanism points toward
the possibility that lithium may inhibit GSK3 with varying lev-
els of efficacy in different cellular/neuronal populations. Indeed,
the formation of βArr2 signaling complexes is dependent upon
the activation of GPCRs (Luttrell et al., 1999) and such com-
plex would only exist in cells that express the specific receptors
(e.g., the D2R) that are responsible for their formation. By dis-
rupting a βArr2 signaling complex that is responsible for the
inhibition of Akt, lithium may, therefore, have a stronger effect
on GSK3 activity in cells in which this complex is formed.
In this case, targeting this complex may confer some level of
selectivity, which may explain why lithium can be useful in
the treatment of bipolar disorders without significantly dis-
rupting GSK3 mediated physiological functions in the whole
organism.
CONCLUSIONS AND FUTURE PERSPECTIVES
Lithium’s mechanism of therapeutic action remains a mystery,
more than 60 years after its first use for the treatment of mania in
a clinical context. This situation has seriously prevented the devel-
opment of improved pharmacotherapies for bipolar disorder.
Some of the data reported in this review indicate that inhibition of
GSK3 either directly or—more possibly—indirectly is a credible
mechanism that may be responsible for some of lithium’s actions.
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However, this remains not solidly established and several addi-
tional studies will be needed to clarify the exact contribution of
GSK3 inhibition in lithium therapy.
A first important question is the role played by GSK3 inhi-
bition in the effects of lithium in humans. Studies conducted
over the past decade have relied mostly on studies conducted
in vertebrates. While this approach is powerful and allows for a
comparison between molecular and behavioral effects of lithium,
it nevertheless remains analogical and correlative. Most of the
behavioral tests used in animals have good predictive validity for
a first evaluation of antimanic or antidepressant like drug effects
(Crawley, 2008). However, these tests certainly do not reflect the
complex and variable symptoms of bipolar disorder in humans.
A logical next step of investigation could be to combine studies of
drug responsiveness in human subjects with different genetic risk
factors that can affect GSK3 activity. In this regard, recent stud-
ies have shown a possible association between a GSK3β promoter
polymorphism and responsiveness to lithium (Benedetti et al.,
2004; Adli et al., 2007; Serretti et al., 2008). However to be truly
convincing such studies should be replicated across independent
laboratories and expended to several risk factors.
The study of GSK3’s involvement in humans would also be
facilitated by the development of surrogate biomarkers for central
nervous system GSK3 activity. The development of such mark-
ers would allow monitoring the activity of GSK3 in patients in
correlation with disease states and responsiveness to treatment.
In line with this, a study has shown that GSK3β phosphory-
lation in peripheral blood cells can be used as an indicator
of responsiveness to treatment (Li et al., 2007). However, this
approach has several limitations as it remains biochemical and
not functional. Future investigations may add to this by estab-
lishing correlates between brain GSK3 activity and, for instance,
physiological/electrophysiological response in peripheral tissue or
changes in brain activity/physiology that can be monitored by
magnetic resonance imaging (Blasi et al., 2011).
In addition to human studies, investigations in mammals
can be expanded to address several questions in rodents and
eventually non-human primates. Among questions that can be
addressed in this way is the identification of molecular targets
that are responsible for the impact of GSK3 activity on behavior.
Furthermore, it would be important to establish neuroanatomi-
cal correlates of GSK3 activity and behavioral regulation. Finally,
animal models probably remain the most powerful tool at our
disposal to understand how lithium acts not on a single molecular
target but on several interconnected cellular signaling networks
to produce its therapeutic actions. For instance, the action of
lithium on both GSK3 and a βArr2 signaling complex that reg-
ulates and is regulated by GSK3 suggests that lithium may affect
GSK3 activity differently in cells that express this signaling com-
plex. To our knowledge, only the D2R has been shown to trigger
the formation of this complex. This is interesting as this receptor
is also a major pharmacological target of antipsychotics (Snyder,
1976; Roth et al., 2004). The relevance of this to the therapeutic
selectivity of lithium and its combined action with antipsychotics
can be further explored by identifying the complement of GPCRs
that are responsible for the formation of this complex and the
impact of these receptors on lithium actions in vivo. Similarly,
lithium does not only affect GSK3 activity but has several other
molecular targets that are also involved in cell signaling (Gould
and Manji, 2002; Beaulieu and Caron, 2008). It would thus be
of interest to use animal models to explore the possible involve-
ment of modulations of cell signaling landscape involving several
of these targets in the overall behavioral effects of lithium. Such
an approach may reveal unexpected and important new infor-
mation that would not be obtainable using a research program
aimed at identifying a single molecular target while excluding
all others.
Overall, recent studies of the involvement of GSK3 in the
action of lithium have established a strong correlation between
GSK3 activity and the regulation of behavior. They have also indi-
cated that lithium is regulating GSK3 not only directly but also
through more complex network effects affecting more than one
molecular target at a time. In the near future, a continuation of
these studies in animal models and the establishment of strong
associations with human data may allow furthering this knowl-
edge. This could lead to the development of an understanding
of the role of GSK3 as well as that of other molecular targets of
lithium in its relatively specific effects on several mental illnesses.
Such knowledge may be the key to the development of new, safer
mood stabilizers having better efficacy and fewer side effects.
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